Uri Elkayam
Cardiovascular Disease · Los Angeles, CANPI 1326086489
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,456 of the $98,155 with a category attached, or 79.9%. 21 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 35.1% of the total. Reporting peaked in 2019 at $43,075 and has fallen 84.9% since, to $6,520 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $934.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$34K
- Johnson & Johnson$29K
- AstraZeneca$8K
- Medtronic$6K
- Amgen$5K
- Vifor Pharma, Inc.$5K
- plus $10K from 15 others
What the payments were for
- Consulting fees$9,52410%
- Speaking & faculty fees$78,45680%
- Travel & lodging$5,6266%
- Food & beverage$4,4525%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $34,411 |
| Johnson & Johnson | 12 | $29,364 |
| AstraZeneca | 13 | $8,074 |
| Medtronic | 3 | $5,604 |
| Amgen | 9 | $5,451 |
| Vifor Pharma, Inc. | 12 | $4,953 |
| Abiomed | 9 | $3,978 |
| Merck | 1 | $3,355 |
| Medicure Pharma Inc. | 2 | $615 |
| Impulse Dynamics (USA) Inc. | 3 | $466 |
| Shockwave Medical, Inc | 2 | $367 |
| E.r. Squibb & Sons, L.L.C. | 3 | $360 |
| Abbott | 4 | $334 |
| Boston Scientific | 3 | $264 |
| Actelion Pharmaceuticals US, Inc. | 3 | $248 |
| Sanofi | 1 | $135 |
| Kestra Medical Technology Services, Inc. | 1 | $63 |
| Biosense Webster, Inc. | 1 | $50 |
| Biotronik Inc. | 1 | $40 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Novartis | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$34,173
- XARELTO$29,234
- LOKELMA$6,904
- EVENITY$5,230
- Prolia$5,230
- Repatha$5,230
- Veltassa$4,591
- Impella$3,834
- VERQUVO$3,355
- FARXIGA$1,074
- OPTIMIZER$931
- ReDS$615
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$367
- CAMZYOS$360
- OPSUMIT$238
- CardioMEMS HF System$138
- FABRAZYME$135
- FREESTYLE LIBRE 3$124
- UPTRAVI$123
- GENERAL TACHY$100
How this compares
$98,155 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.